Center Laboratories Inc (晟德大藥廠), which makes oral liquid formulations, has signed a memorandum of understanding that would pave the way for a lucrative out-licensing deal with a Chinese partner.
Through the deal, the company plans to license CS02, its diabetes drug candidate, to CR Pharmaceutical Group (華潤集團) to tap into the Chinese market, Center Laboratories said on Friday last week.
The deal is expected to bring in 80 million yuan (US$11.96 million) in signing bonuses and milestone payments, the company said in a statement.
The windfall would boost the company’s earnings per share performance by NT$1.12, it said.
Center Laboratories, which has touted itself as a leading private-equity investor in the biotechnology sector, comparable to the Blackstone Group, expects to retain royalties as a double-digit percentage of net sales of the drug, it added.
A CR Pharmaceutical Group subsidiary would be responsible for development expenses in bringing CS02 to the Chinese market, including further clinical trials and filings for regulatory approval and registrations, as well as marketing and distribution post-approval, Center Laboratories said.
CS02 has enrolled type II diabetes patients and begun phase II clinical trials in Taiwan and the US, which are expected to be completed in 2020 and next year respectively.
“The new drug is designed to restore impaired beta-cells and improve diabetes care, and could potentially treat and reverse both type 1 and type 2 diabetes, while conventional treatments seek to help patients contain blood sugar levels,” Center Laboratories said.
China has the world’s largest population of diabetic patients, about 114 million people or 10.9 percent of the country’s population.
This increasing trend is likely to continue, Center Laboratories said, citing findings by the International Diabetic Federation.
The company’s revenue last month jumped 59.19 percent year-on-year to NT$2.83 billion (US$92.62 million), with contributions coming from its subsidiaries Ausnutria Dairy Corp (澳優乳業) and Glac Biotech Co Ltd (豐華生物科技), as well as from its various oral medical solutions, Center Laboratories said on Tuesday last week.
Cumulative sales in the first six months of this year increased 55.01 percent annually to NT$13.09 billion, it said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day